Piper Jaffray Reiterates Overweight on SLXP

Piper Jaffray has issued a report reiterating the Overweight Rating on Salix Pharmaceuticals SLXP. ACcording to the report, "We spent yesterday with Salix senior management meeting with investors. We came away with even greater confidence that there is a reasonable path forward for Xifaxan in irritable bowel syndrome (IBS), and with greater confidence in the overall trajectory of the in-market product portfolio." SLXP has a $47 Price Target and closed at $38.79 a share yesterday.